Literature DB >> 31032088

Natural killer NKG2A and NKG2D in patients with colorectal cancer.

Ghada R Meckawy1, Ahmed M Mohamed1, Wafaa K Zaki2, Mona A Khattab2, Mariam M Amin3, Mai A ElDeeb3, Marwa R El-Najjar4, Nesma A Safwat4.   

Abstract

BACKGROUND: Natural-killer group 2 (NKG2), a characteristic receptor of natural killer (NK) cell family, assumes a vital role in modulating NK cytotoxic function. We aimed to detect mRNA expression of both NKG2A and NKG2D in serum NK cells obtained from colorectal cancer (CRC) patients.
METHODS: We enrolled 36 patients with newly diagnosed CRC, as well as 15 group matched healthy individuals. The patients were further classified into: 23 non-metastatic CRC (group 1) and 13 metastatic CRC (group 2). We detected the expression of NKG2A and NKG2D serum levels for all participants utilizing real-time polymerase chain reaction (RT-PCR).
RESULTS: NKG2D and NKG2A mRNA levels in peripheral blood mononuclear cells (PBMCs) were significantly elevated in patients with CRC compared to controls (P<0.01). NKG2D or NKG2A showed sensitivity (77.8, 83.33%) and specificity (73.33, 100%) respectively using receiver-operating characteristic (ROC) curve analysis for discrimination between patients and controls, whereas group 1 and group 2 showed no statistical significant difference in NKG2D and NKG2A levels (P>0.05).
CONCLUSIONS: Our work is one of the first research that could detect an increase in NKG2D in CRC. In spite of their defensive role in tumor immune surveillance, NKG2D and NKG2A and their ligands could have misused as tumor survival tool, empowering immune avoidance and suppression.

Entities:  

Keywords:  Colorectal cancer (CRC); NKG2A; NKG2D; mRNA; natural-killer cells (NK cells)

Year:  2019        PMID: 31032088      PMCID: PMC6465484          DOI: 10.21037/jgo.2018.12.13

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  43 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin.

Authors:  D Pende; C Cantoni; P Rivera; M Vitale; R Castriconi; S Marcenaro; M Nanni; R Biassoni; C Bottino; A Moretta; L Moretta
Journal:  Eur J Immunol       Date:  2001-04       Impact factor: 5.532

3.  Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation.

Authors:  Veronika Groh; Jennifer Wu; Cassian Yee; Thomas Spies
Journal:  Nature       Date:  2002-10-17       Impact factor: 49.962

4.  Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells.

Authors:  V Groh; R Rhinehart; J Randolph-Habecker; M S Topp; S R Riddell; T Spies
Journal:  Nat Immunol       Date:  2001-03       Impact factor: 25.606

Review 5.  Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999.

Authors:  C C Compton; L P Fielding; L J Burgart; B Conley; H S Cooper; S R Hamilton; M E Hammond; D E Henson; R V Hutter; R B Nagle; M L Nielsen; D J Sargent; C R Taylor; M Welton; C Willett
Journal:  Arch Pathol Lab Med       Date:  2000-07       Impact factor: 5.534

6.  Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells.

Authors:  Roberta Castriconi; Claudia Cantoni; Mariella Della Chiesa; Massimo Vitale; Emanuela Marcenaro; Romana Conte; Roberto Biassoni; Cristina Bottino; Lorenzo Moretta; Alessandro Moretta
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-19       Impact factor: 11.205

7.  Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.

Authors:  Ekaterina S Doubrovina; Mikhail M Doubrovin; Elena Vider; Richard B Sisson; Richard J O'Reilly; Bo Dupont; Yatin M Vyas
Journal:  J Immunol       Date:  2003-12-15       Impact factor: 5.422

8.  Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients.

Authors:  June-Chul Lee; Kyung-Mi Lee; Dong-Wan Kim; Dae Seog Heo
Journal:  J Immunol       Date:  2004-06-15       Impact factor: 5.422

Review 9.  The three Es of cancer immunoediting.

Authors:  Gavin P Dunn; Lloyd J Old; Robert D Schreiber
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

Review 10.  Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis.

Authors:  A Moretta; C Bottino; M Vitale; D Pende; C Cantoni; M C Mingari; R Biassoni; L Moretta
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

View more
  3 in total

Review 1.  The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy.

Authors:  Haoyu Sun; Cheng Sun
Journal:  Front Immunol       Date:  2019-10-17       Impact factor: 7.561

Review 2.  Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy.

Authors:  Yuqing Cao; Xiaoyu Wang; Tianqiang Jin; Yu Tian; Chaoliu Dai; Crystal Widarma; Rui Song; Feng Xu
Journal:  Signal Transduct Target Ther       Date:  2020-10-29

3.  Potential prognostic value of PD-L1 and NKG2A expression in Indonesian patients with skin nodular melanoma.

Authors:  Ridwan Dwi Saputro; Hanggoro Tri Rinonce; Yayuk Iramawasita; Muhammad Rasyid Ridho; Maria Fransiska Pudjohartono; Sumadi Lukman Anwar; Kunto Setiaji; Teguh Aryandono
Journal:  BMC Res Notes       Date:  2021-05-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.